Dr. Waleed A Hashem

Dr. Waleed A Hashem |Clyto Access

King Saud Medical City, Saudi Arabia

Organizing Committee Member

Expertise: Endocrinology and diabetes


Dr. Waleed Hashem presently serves as head of endocrinology and diabetes division and the program director of endocrinology and metabolism fellowship at King Saud Medical City (KSMC) in Riyadh, Saudi Arabia. He is a clinical assistant professor in al-imam Mohammed Ibn Saud University and fellow of the American College of Endocrinology. As well as he is a Clinical Instructor in the internal medicine postgraduate program. Dr. Hashem received his MBBS degree from King Saud University and completed Internal Medicine residency training program at King Saud Medical City in Riyadh. Subsequently, he completed his training in Endocrinology and Metabolism at King Faisal Specialist Hospital and Research Center (KFSH&RC)in Riyadh. Then he received his fellowship degree in metabolic bone diseases after he completed his training at McMaster University in Hamilton, Canada. He got a certificate in clinical densitometry in 2016. Dr. Hashemhas presented a number of oral and poster abstracts internationally in the field of endocrinology, osteoporosis and bone metabolism. He was selected to receive Young Investigator Award from International Society for Clinical Densitometry (ISCD) in Feb. 2015. Dr. Hashem is the primary author of Hypercalcemia Chapter in one of the unique reference book in the field of endocrine diseases was published in Jan. 2017 named “medical and surgical treatment of parathyroid diseases”.



Title: Diabetes and Osteoporosis. “Sweet fragility bone fractures”


Diabetes and osteoporosis are common disorders and they may therefore occur concurrently by chance. However, a growing body of evidence suggests that hyperglycemia may impair bone matrix formation and biochemical competence. Osteoporosis is characterized by disturbance of bone strength either in its density and/or its quality leading to an increased risk of fracture.In patients with diabetes, bone turnover isreduced and many factors contribute to this reduction such as insulin deficiency, hypercalciuria secondary to elevated blood glucose and accumulation of advance glycosylation end products in collagen.In general, low bone mineral density (BMD) was found in patients with type 1 diabetes while the majority of patients with type 2 diabetes have either normal or increase in BMD. In spite the difference in bone density finding in both types of diabetes, most studieshave showed an increased risk of bone fracture in both groups.These resultsmay indicate bone quality disruption in those patients as well. Many factors might play a role in developing osteoporotic fracture in patients with diabetes such duration of diabetes, renal and neurological diabetic complications, increased risk of falling, and administration of drugs as thiazolidinedione.


Related Conferences :

International Diabetes and Degenerative Diseases Conference